Consumer Radar

  The global Car Insurance Market was valued at USD 949.2 million in 2025 and is projected to reach USD 3.51 billion by 2035, growing at a CAGR of 14% over the forecast period (2026–2035). This rapid expansion reflects rising vehicle ownership in emerging economies, accelerating digital distribution and telematics adoption, heightened regulatory requirements for motor coverage, and an expanding suite of add-on motor products that drive policy depth and lifetime value. Car Insurance Industry Demand Market Description Car insurance provides financial protection against physical damage, liability, theft, and bodily injury resulting from automobile incidents. Coverage frameworks vary by jurisdiction but generally include compulsory third-party liability and optional comprehensive and collision covers. The modern car-insurance ecosystem now spans product underwriting, claims management, loss control, telematics, usage-based pricing, and partnerships with OEMs, mobility providers,...

  The Technology Licensing Market has become a core enabler of innovation transfer, competitive differentiation, and intellectual property (IP) monetization across industries. In 2025 , the market size exceeded USD 2.1 billion . By 2035 , it is projected to reach USD 5.6 billion , expanding at a robust CAGR of 11.7% during the forecast timeline ( 2026–2035 ). This growth trajectory reflects escalating technology convergence, rising R&D outsourcing, expanding patent portfolios, and organizations increasingly shifting toward asset-light innovation models. The market continues to surge as companies seek faster commercialization pathways, reduce internal development costs, and protect proprietary knowledge while simultaneously unlocking new revenue streams. Technology Licensing Industry Demand The Technology Licensing Market refers to the ecosystem in which organizations license technological assets—such as patents, proprietary platforms, know-how, software, trade secrets,...

  The Duchenne Muscular Dystrophy (DMD) Drugs Market comprises pharmacological and biological therapies intended to slow, halt, or reverse the progressive muscle degeneration caused by mutations in the dystrophin gene. The market spans symptomatic treatments (corticosteroids, anti-inflammatories), disease-modifying modalities (exon-skipping antisense oligonucleotides, stop-codon read-through agents), and next-generation approaches (gene-replacement therapy, gene editing, cell therapy, and myostatin inhibition). Manufacturers, biotech innovators, clinical research organizations, and specialized care centers form the ecosystem supporting drug development, regulatory approval, and commercialization. Duchenne Muscular Dystrophy Drugs Industry Demand Demand for DMD drugs is shaped by clinical urgency, technological possibility, and evolving healthcare economics: ·          Clinical Need & Unmet Medical Demand: DMD is a severe, progress...